Progressive Pericardial Effusions (PEF) in Patients With Pulmonary Arterial Hypertension (PAH) Taking Sotatercept—Association With Pre‐Existing Pericardial Effusion
Pericardial effusion (PEF) in PAH may be a marker of worsening disease or associated with autoimmune conditions. Sotatercept was not initially reported as associated with the development or progression of PEF. We describe PAH patients taking sotatercept who were found to have new or worsening PEF and examine associated comorbidities.
Authors
- Hilamber Subba (ORCID: https://orcid.org/0000-0001-8102-7050)
- John Gilboy
- Jacob Gelman
- Tapan Mehta
- Rachel Cutting (ORCID: https://orcid.org/0000-0002-6786-1097)
- Hemant K. Roy (ORCID: https://orcid.org/0000-0001-7613-5575)
- Joel A. Wirth
- Kellie Ramsdell
Institutions
- Maine Medical Center (US)
- Maine Medical Center (US)
Publication Details
- Journal
- Pulmonary Circulation
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/pul2.70215
- Citations
- 1
- Primary Topic
- Pericarditis and Cardiac Tamponade
- Type
- article
- Field-Weighted Citation Impact
- 1.39